Nosa Med AB
Nosa Plugs AB, a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, rest of Europe, the United States, Canada, and internationally. The company offers NOSA allergy filter that filters airborne allergens, such as pollen, pet dander, dust, and mold; NOSA smell training, a smell training medical device to improve the sense of smell for individuals … Read more
Nosa Med AB (NOSA) - Net Assets
Latest net assets as of September 2025: Skr41.71 Million SEK
Based on the latest financial reports, Nosa Med AB (NOSA) has net assets worth Skr41.71 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr67.06 Million) and total liabilities (Skr25.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr41.71 Million |
| % of Total Assets | 62.19% |
| Annual Growth Rate | -25.15% |
| 5-Year Change | -83.71% |
| 10-Year Change | N/A |
| Growth Volatility | 35.48 |
Nosa Med AB - Net Assets Trend (2016–2024)
This chart illustrates how Nosa Med AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nosa Med AB (2016–2024)
The table below shows the annual net assets of Nosa Med AB from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr16.56 Million | -38.11% |
| 2023-12-31 | Skr26.75 Million | +45.90% |
| 2022-12-31 | Skr18.34 Million | -53.11% |
| 2021-12-31 | Skr39.10 Million | -61.53% |
| 2020-12-31 | Skr101.64 Million | -45.89% |
| 2019-12-31 | Skr187.85 Million | -6.26% |
| 2018-12-31 | Skr200.39 Million | +4.25% |
| 2017-12-31 | Skr192.22 Million | +14.38% |
| 2016-12-31 | Skr168.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nosa Med AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8013500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr10.51 Million | 63.48% |
| Other Components | Skr109.55 Million | 661.69% |
| Total Equity | Skr16.56 Million | 100.00% |
Nosa Med AB Competitors by Market Cap
The table below lists competitors of Nosa Med AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Practical Solution Public Company Limited
BK:TPS
|
$10.96 Million |
|
Pacific Orient Bhd
KLSE:6009
|
$10.96 Million |
|
Shalimar Paints Limited
NSE:SHALPAINTS
|
$10.96 Million |
|
Revium Recovery Inc
PINK:RVRC
|
$10.96 Million |
|
Advtech
JSE:ADH
|
$10.95 Million |
|
Renova Energia S.A
SA:RNEW11
|
$10.95 Million |
|
Amata VN PCL
BK:AMATAV
|
$10.95 Million |
|
Oncoclinicas do Brasil
SA:ONCO3
|
$10.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nosa Med AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,750,000 to 16,556,000, a change of -10,194,000 (-38.1%).
- Net loss of 10,158,000 reduced equity.
- Other comprehensive income decreased equity by 17,498,000.
- Other factors increased equity by 17,462,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-10.16 Million | -61.36% |
| Other Comprehensive Income | Skr-17.50 Million | -105.69% |
| Other Changes | Skr17.46 Million | +105.47% |
| Total Change | Skr- | -38.11% |
Book Value vs Market Value Analysis
This analysis compares Nosa Med AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.05x to 6.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr11.22 | Skr0.53 | x |
| 2017-12-31 | Skr11.03 | Skr0.53 | x |
| 2018-12-31 | Skr9.98 | Skr0.53 | x |
| 2019-12-31 | Skr7.59 | Skr0.53 | x |
| 2020-12-31 | Skr3.20 | Skr0.53 | x |
| 2021-12-31 | Skr0.81 | Skr0.53 | x |
| 2022-12-31 | Skr0.11 | Skr0.53 | x |
| 2023-12-31 | Skr0.17 | Skr0.53 | x |
| 2024-12-31 | Skr0.08 | Skr0.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nosa Med AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -63.10%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.25x
- Recent ROE (-61.36%) is above the historical average (-106.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -10.89% | 0.00% | 0.00x | 1.02x | Skr-35.11 Million |
| 2017 | -12.95% | -10037.90% | 0.00x | 1.04x | Skr-44.12 Million |
| 2018 | -20.97% | -799.52% | 0.02x | 1.07x | Skr-62.05 Million |
| 2019 | -39.27% | -3810.07% | 0.01x | 1.08x | Skr-92.55 Million |
| 2020 | -225.42% | -16760.42% | 0.01x | 1.14x | Skr-239.28 Million |
| 2021 | -149.76% | -1000.43% | 0.15x | 1.03x | Skr-62.48 Million |
| 2022 | -266.00% | -260.18% | 0.32x | 3.23x | Skr-18.49 Million |
| 2023 | -174.03% | -447.94% | 0.31x | 1.24x | Skr-49.23 Million |
| 2024 | -61.36% | -63.10% | 0.78x | 1.25x | Skr-11.81 Million |
Industry Comparison
This section compares Nosa Med AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nosa Med AB (NOSA) | Skr41.71 Million | -10.89% | 0.61x | $10.96 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |